Chen Jinxing, Tang Yanan, Shen Zekun, Wang Weiyi, Hou Jiaxuan, Li Jiayan, Chen Bingyi, Mei Yifan, Liu Shuang, Zhang Liwei, Lu Shaoying
Department of Vascular Surgery, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, Shaanxi, P. R. China.
J Endovasc Ther. 2024 Dec;31(6):1140-1149. doi: 10.1177/15266028231158294. Epub 2023 Mar 8.
This study aimed to develop and internally validate nomograms for predicting restenosis after endovascular treatment of lower extremity arterial diseases.
A total of 181 hospitalized patients with lower extremity arterial disease diagnosed for the first time between 2018 and 2019 were retrospectively collected. Patients were randomly divided into a primary cohort (n=127) and a validation cohort (n=54) at a ratio of 7:3. The least absolute shrinkage and selection operator (LASSO) regression was used to optimize the feature selection of the prediction model. Combined with the best characteristics of LASSO regression, the prediction model was established by multivariate Cox regression analysis. The predictive models' identification, calibration, and clinical practicability were evaluated by the C index, calibration curve, and decision curve. The prognosis of patients with different grades was compared by survival analysis. Internal validation of the model used data from the validation cohort.
The predictive factors included in the nomogram were lesion site, use of antiplatelet drugs, application of drug coating technology, calibration, coronary heart disease, and international normalized ratio (INR). The prediction model demonstrated good calibration ability, and the C index was 0.762 (95% confidence interval: 0.691-0.823). The C index of the validation cohort was 0.864 (95% confidence interval: 0.801-0.927), which also showed good calibration ability. The decision curve shows that when the threshold probability of the prediction model is more significant than 2.5%, the patients benefit significantly from our prediction model, and the maximum net benefit rate is 30.9%. Patients were graded according to the nomogram. Survival analysis found that there was a significant difference in the postoperative primary patency rate between patients of different classifications (log-rank p<0.001) in both the primary cohort and the validation cohort.
We developed a nomogram to predict the risk of target vessel restenosis after endovascular treatment by considering information on lesion site, postoperative antiplatelet drugs, calcification, coronary heart disease, drug coating technology, and INR.
Clinicians can grade patients after endovascular procedure according to the scores of the nomograms and apply intervention measures of different intensities for people at different risk levels. During the follow-up process, an individualized follow-up plan can be further formulated according to the risk classification. Identifying and analyzing risk factors is essential for making appropriate clinical decisions to prevent restenosis.
本研究旨在开发并进行内部验证用于预测下肢动脉疾病血管内治疗后再狭窄的列线图。
回顾性收集2018年至2019年期间首次诊断为下肢动脉疾病的181例住院患者。患者按7:3的比例随机分为初级队列(n = 127)和验证队列(n = 54)。采用最小绝对收缩和选择算子(LASSO)回归优化预测模型的特征选择。结合LASSO回归的最佳特征,通过多变量Cox回归分析建立预测模型。通过C指数、校准曲线和决策曲线评估预测模型的辨别力、校准度和临床实用性。通过生存分析比较不同分级患者的预后。模型的内部验证使用验证队列的数据。
列线图纳入的预测因素包括病变部位、抗血小板药物的使用、药物涂层技术的应用、校准、冠心病和国际标准化比值(INR)。预测模型显示出良好的校准能力,C指数为0.762(95%置信区间:0.691 - 0.823)。验证队列的C指数为0.864(95%置信区间:0.801 - 0.927),也显示出良好的校准能力。决策曲线表明,当预测模型的阈值概率大于2.5%时,患者从我们的预测模型中显著获益,最大净获益率为30.9%。根据列线图对患者进行分级。生存分析发现,在初级队列和验证队列中,不同分类患者的术后原发性通畅率均存在显著差异(对数秩检验p < 0.001)。
我们通过考虑病变部位、术后抗血小板药物、钙化、冠心病、药物涂层技术和INR等信息,开发了一种列线图来预测血管内治疗后靶血管再狭窄的风险。
临床医生可根据列线图的评分对血管内手术后的患者进行分级,并对不同风险水平的人群采取不同强度的干预措施。在随访过程中,可根据风险分类进一步制定个体化的随访计划。识别和分析风险因素对于做出适当的临床决策以预防再狭窄至关重要。